On Friday, Kevenue, the maker of Tylenol, saw its stocks drop more than 10% after the Wall Street Journal reported that Health and Human Services Secretary Robert F. Kennedy plans to release a federal report connecting prenatal use of Tylenol to autism. As Kennedy and his appointed vaccine panel continue to erode vaccine recommendations, many… The post Vaccine makers’ stocks continue to spiral as the segment faces fresh pressures appeared first on Drug Discovery and Development.| Drug Discovery and Development
DREAMM-7-studien til GSK demonstrerte solide 36,6 måneders median progresjonsfri overlevelse hos myelomatose-pasienter som fikk Blenrep-kombinasjon. – Veldig spennende å se at dette faktisk er et mer effektivt medikament enn daratumumab, sier hematolog Fredrik Schjesvold.| www.healthtalk.no
GSK took center stage last month, forming standout partnerships and alliances across multiple therapeutic areas.| Labiotech.eu
